Stiftung zur förderung der erforschung von ersatz- und ergänzungsmethoden zur einschränkung von tierversuchen

Stiftung zur Förderung der Erforschung von Ersatz- und Ergänzungsmethoden zur Einschränkung von Tierversuchen Mainzer Landstraße 55, 60329 Frankfurt am Main Completed Project
Pharmacological Screening using human embryonic stem cell Dr. Michael Reppel, Institut für Neurophysiologie, Universität Köln Pharmacological Screening using human embryonic stem cell derived

Screening of drug safety is typically performed in diverse non-human healthy species with an intact
repolarization reserve. Nevertheless, these drugs are later applied in diseased humans with a
reduced repolarization reserve. It would be optimal to set up a preclinical screening tool to estimate
the proarrhythmic potential of drugs in human cardiac tissue with a reduced repolarization reserve in
Methods and Results:

In our study spontaneously beating human embryonic stem cell-derived cardiomyocytes clusters
(hESCM) and murine ES cell-derived cardiomyocytes (mESCMs) were plated onto micro-electrode
arrays (MEAs, fig. 1) to record the extracelluar field potentials (FPs) as well as effects of several
antiarrhythmic drugs. In line with clinical observations the class III antiarrhythmic drugs (±)-sotalol,
E4031 and class I antiarrhythmic drug quinidine led to a prolongation of the cardiac repolarization
phase (FP duration, FPdur) and a decrease of the FP frequency. Verapamil (a class IV antiarrhythmic
drug) decreased the FP frequency and shortened FPdur. Both, quinidine and verapamil, but not (±)-
sotalol or E4031 decreased conduction velocities in hESCM clusters.
Moreover, (±)-sotalol exerted stronger effects on FPdur in early developmental stages of hESCMs, as
proof for a reduced repolarization reserve. The EC50 of the (±)-sotalol-induced prolongation of the
FPdur was higher in mESCMs than in hESCMs implying species-dependent differences in cardiac
repolarization. Likewise, the incidence of drug-induced early recurrent depolarization (ERDs) was
higher in mESCMs than hESCMs. Conclusion: The combined measurement of drug effects on FP
parameters in hESCMs and mESCMs serves as a reliable in vitro model for preclinical studies of drug
Copyright 2010 S. Karger AG, Basel
Fig. 1: MEA-Components (Multi Channel Systems, Germany): The standard substrate-integrated MEA culture
dish contains 60 Titanium Nitride coated gold electrodes (30 μm diameter) arranged in an 8x8 electrode grid
with an interelectrode distance of 200 μm, allowing simultaneous recording of extracellular FPs from all
electrodes at a sampling rate of 1 to 25 kHz by the use of the MEA amplifier system.
Liang H, Matzkies M, Schunkert H, Tang M, Bonnemeier H, Hescheler J, Reppel M. Human and murine
embryonic stem cell-derived cardiomyocytes serve together as a valuable model for drug safety screening.
Cell Physiol Biochem. 2010;25(4-5):459-66. Epub 2010 Mar 23.


Jake olivier

Jake Olivier, Ph.D. PEER-REVIEWED JOURNAL ARTICLES * Supervision of student or post-doc in underline 1. Heinzelmann-Schwarz VA, Nixdorf S, Valadan M, Diczbalis M, Olivier J , Otton G, Fedier A, Hacker NF & Scurry JP. A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker. International Journal of Molecular Medicine , accept

Microsoft powerpoint - acct - biotech seminar - fenwick.pptx

1. Utility and Promise of the Patent2. Disclosure requirements – post-Viagra®3. Methods of Medical Treatment - Dosage Demonstrated Utility • No actual data needed in application as filed• If no data, application as filed must include reference to a study supporting claimed utility• Utility must be proven upon challenge• Support for utility must be present at Canadian (

Copyright © 2010 Find Medical Article